A Phase 1 interventional study of IBI3016 Dose 4 and IBI3016 Dose 3 in Hypertension, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Hypertension with a site in Japan — 11 open to participants now, 17 under way, 8 of them phase 3. Hypertension · Japan.
Among the 142 studies in Hypertension with a site in Japan, this one is the 112th largest by planned enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 3 of the 16 other live ones, and was the 141st registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →11 of the 142 studies in Hypertension with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Argentina and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Japan, United States, Singapore
Ages 18+
Alnylam Pharmaceuticals · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
Boehringer Ingelheim · Sites in Japan, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 50 · Phase 4 41
First in 2000; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 237 across the 125 interventional studies, 1,452 across the 17 observational. Of the 105 that completed or were terminated, 48 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 142 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension with a site in Japan that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT05326230Otsuka Medical Devices Co., Ltd. JapanA Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO) | 2026-12 |
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 142 studies in Hypertension with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single doses of IBI3016 administered by subcutaneous injection
Drug: IBI3016 Dose 1
single doses of IBI3016 administered by subcutaneous injection
Drug: IBI3016 Dose 2
single doses of IBI3016 administered by subcutaneous injection
Drug: IBI3016 Dose 4
single doses of Placebo administered by subcutaneous injection
Drug: Placebo
single doses of IBI3016 administered by subcutaneous injection
Drug: IBI3016 Dose 3
single doses of IBI3016 administered by subcutaneous injection
single doses of IBI3016 administered by subcutaneous injection
single doses of IBI3016 administered by subcutaneous injection
single doses of IBI3016 administered by subcutaneous injection
single doses of IBI3016 administered by subcutaneous injection
Number of Participants with Adverse Events
Time frame: Through 24 weeks, up to approximately 12 months
Plasma Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI3016
Time frame: Predose, early post-dose and up to 48 hours postdose
Plasma PK: Area Under the Concentration Versus Time Curve (AUC) of IBI3016
Time frame: Predose, Day 1, and up to 48 hours postdose
Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) assessed by OBP and ABPM
Time frame: Baseline, Month 3 and Month 6
Change from baseline in serum angiotensinogen (AGT) concentration
Time frame: Through 24 weeks, up to approximately 12 months
Urine PK parameter: drug accumulation
Time frame: Predose, Day 1, and up to 48 hours postdose
Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 5 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IBI3016
Innovent Biologics (Suzhou) Co. Ltd. →